These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 36269898)
1. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898 [TBL] [Abstract][Full Text] [Related]
2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021 [TBL] [Abstract][Full Text] [Related]
3. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469 [TBL] [Abstract][Full Text] [Related]
4. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883 [TBL] [Abstract][Full Text] [Related]
5. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Hansen DK; Lu X; Puglianini OC; Sorensen S; Usmani SZ; Zhang E; Huo S; Zhang Y; Qureshi ZP; Jagannath S Front Immunol; 2024; 15():1408892. PubMed ID: 39234256 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989 [TBL] [Abstract][Full Text] [Related]
8. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Martin TG; Madduri D; Pacaud L; Usmani SZ Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629 [TBL] [Abstract][Full Text] [Related]
9. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. San-Miguel J; Dhakal B; Yong K; Spencer A; Anguille S; Mateos MV; Fernández de Larrea C; Martínez-López J; Moreau P; Touzeau C; Leleu X; Avivi I; Cavo M; Ishida T; Kim SJ; Roeloffzen W; van de Donk NWCJ; Dytfeld D; Sidana S; Costa LJ; Oriol A; Popat R; Khan AM; Cohen YC; Ho PJ; Griffin J; Lendvai N; Lonardi C; Slaughter A; Schecter JM; Jackson CC; Connors K; Li K; Zudaire E; Chen D; Gilbert J; Yeh TM; Nagle S; Florendo E; Pacaud L; Patel N; Harrison SJ; Einsele H N Engl J Med; 2023 Jul; 389(4):335-347. PubMed ID: 37272512 [TBL] [Abstract][Full Text] [Related]
10. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477 [TBL] [Abstract][Full Text] [Related]
11. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma. Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG Expert Opin Biol Ther; 2024 May; 24(5):339-350. PubMed ID: 38738379 [TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668 [TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210 [TBL] [Abstract][Full Text] [Related]
14. Ciltacabtagene autoleucel for the treatment of multiple myeloma. Holstein SA Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414 [TBL] [Abstract][Full Text] [Related]
15. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T Front Immunol; 2022; 13():991092. PubMed ID: 36119032 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Cohen AD; Mateos MV; Cohen YC; Rodriguez-Otero P; Paiva B; van de Donk NWCJ; Martin T; Suvannasankha A; De Braganca KC; Corsale C; Schecter JM; Varsos H; Deraedt W; Wang L; Vogel M; Roccia T; Xu X; Mistry P; Zudaire E; Akram M; Nesheiwat T; Pacaud L; Avivi I; San-Miguel J Blood; 2023 Jan; 141(3):219-230. PubMed ID: 36095849 [TBL] [Abstract][Full Text] [Related]
17. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872 [TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966 [TBL] [Abstract][Full Text] [Related]
19. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590 [TBL] [Abstract][Full Text] [Related]
20. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]